Category
    Regions
    Category
    Regions
    Reset Showing 1 – 10 of 68
    Teladoc Health Inc. SWOT, Financial and Strategic Analysis Report 2025

    Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Teladoc Health Inc.. Teladoc Health Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Teladoc Health Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Teladoc Health Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Teladoc Health Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Teladoc Health Inc. and all latest updates of the company are provided. The 2025 version of Teladoc Health Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Sep-2025

    $100
    UPTO 50% OFF
    $100
    $100
    UPTO 50% OFF
    Renalytix plc American Depositary Shares SWOT, Financial and Strategic Analysis Report 2025

    Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Renalytix plc American Depositary Shares. Renalytix plc American Depositary Shares business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Renalytix plc American Depositary Shares are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Renalytix plc American Depositary Shares , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Renalytix plc American Depositary Shares including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Renalytix plc American Depositary Shares and all latest updates of the company are provided. The 2025 version of Renalytix plc American Depositary Shares report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    R1 RCM Inc. SWOT, Financial and Strategic Analysis Report 2025

    R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of R1 RCM Inc.. R1 RCM Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of R1 RCM Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of R1 RCM Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of R1 RCM Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of R1 RCM Inc. and all latest updates of the company are provided. The 2025 version of R1 RCM Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Quality Systems, Inc. SWOT, Financial and Strategic Analysis Report 2025

    NextGen Healthcare, Inc. provides healthcare technology solutions in the United States. The company offers clinical care solutions, including NextGen Enterprise EHR; financial solutions, such as NextGen Enterprise PM; patient engagement solutions comprising NextGen Virtual Visits; integrated clinical care and financial solutions consisting of NextGen Office; interoperability solutions that include NextGen Share and Mirth Connect; data and analytics solutions, which comprise NextGen Health Data Hub; and value based care solutions, including NextGen Population Health Solutions. It also provides managed services, such as revenue cycle management services comprising billing and collections, electronic claims submission and denials management, electronic remittance and payment posting, and accounts receivable follow-up; and client and support services. Further, the company offers professional services consisting of training, project management, installation services, and application managed services; and consulting services that include physician, professional, and technical consulting; assisting clients to optimize their staffing and software solutions; enhancing financial and clinical outcomes; achieving regulatory requirements; and meeting the requirements of healthcare reform. It serves accountable care organizations, independent physician associations, managed service organizations, veterans service organizations, dental service organizations, ambulatory care centers, and community health centers through a direct sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was incorporated in 1974 and is headquartered in Atlanta, Georgia. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Quality Systems, Inc.. Quality Systems, Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Quality Systems, Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Quality Systems, Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Quality Systems, Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Quality Systems, Inc. and all latest updates of the company are provided. The 2025 version of Quality Systems, Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Progyny Inc. SWOT, Financial and Strategic Analysis Report 2025

    Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Progyny Inc.. Progyny Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Progyny Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Progyny Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Progyny Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Progyny Inc. and all latest updates of the company are provided. The 2025 version of Progyny Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Privia Health Group Inc. SWOT, Financial and Strategic Analysis Report 2025

    Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Privia Health Group Inc.. Privia Health Group Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Privia Health Group Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Privia Health Group Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Privia Health Group Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Privia Health Group Inc. and all latest updates of the company are provided. The 2025 version of Privia Health Group Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Premier Inc. SWOT, Financial and Strategic Analysis Report 2025

    Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; STOCKD, an e-commerce platform; PROVIDEGX program, which identifies supply sources for drugs that are on or may be at risk of being added to the national drug shortage list, or that are vulnerable to pricing volatility, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company also provides services to other businesses, including food service, schools, and universities. Premier, Inc. was incorporated in 2013 and is headquartered in Charlotte, North Carolina. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Premier Inc.. Premier Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Premier Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Premier Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Premier Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Premier Inc. and all latest updates of the company are provided. The 2025 version of Premier Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Phreesia Inc. SWOT, Financial and Strategic Analysis Report 2025

    Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Phreesia Inc.. Phreesia Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Phreesia Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Phreesia Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Phreesia Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Phreesia Inc. and all latest updates of the company are provided. The 2025 version of Phreesia Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Pharma-Bio Serv, Inc. SWOT, Financial and Strategic Analysis Report 2025

    Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Pharma-Bio Serv, Inc.. Pharma-Bio Serv, Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Pharma-Bio Serv, Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Pharma-Bio Serv, Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Pharma-Bio Serv, Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Pharma-Bio Serv, Inc. and all latest updates of the company are provided. The 2025 version of Pharma-Bio Serv, Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF
    Pear Therapeutics Inc. SWOT, Financial and Strategic Analysis Report 2025

    Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Pear Therapeutics Inc.. Pear Therapeutics Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Pear Therapeutics Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Pear Therapeutics Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Pear Therapeutics Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Pear Therapeutics Inc. and all latest updates of the company are provided. The 2025 version of Pear Therapeutics Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 50% OFF
    $50
    $50
    UPTO 50% OFF